Wed Sep 18 06:46:52 UTC 2024: ## American Healthcare REIT Stock Soars on Positive Analyst Reviews
**New York, NY – September 18, 2024** – American Healthcare REIT (NYSE: AHR) is experiencing a surge in its stock price following a series of positive analyst reviews. KeyCorp, in particular, has increased its price target for AHR from $16.00 to $27.00, representing a potential upside of 11.16% from the previous close. The firm currently maintains an “overweight” rating on the stock.
This optimistic outlook is echoed by other analysts. JMP Securities raised their price objective to $18.00, while Bank of America upped theirs to $27.00, both assigning “market outperform” and “buy” ratings respectively. Morgan Stanley and Truist Financial also increased their price targets, reaching $22.00 each, with “overweight” and “buy” ratings respectively.
This positive sentiment is reflected in the overall consensus rating for AHR, which stands at “Moderate Buy” with a consensus price target of $20.38.
Despite missing earnings expectations in the recent quarter, the company’s strong revenue growth of 7.9% year-over-year has fueled positive investor sentiment. Additionally, the company’s large asset base, totaling approximately $4.2 billion in gross investment value, positions it as a major player in the global healthcare real estate market.
Institutional investors remain optimistic, with 16.68% of the company’s stock owned by institutional investors. Several funds have recently increased their positions in AHR, indicating confidence in the company’s future prospects.
While the recent earnings miss raises some concerns, the strong analyst support, positive revenue growth, and large asset base suggest that AHR remains a promising investment opportunity in the healthcare real estate sector.
First Piper 